Press Release August 6, 2021Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs 0 0 Share
Company Ticker News July 21, 2021Aprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-Transplant 0 0 Share
Company Ticker News June 17, 2021Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal 0 0 Share
